Atrasentan (Microvascular Complications of Diabetes)：市場予測と分析（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 9
1.2 List of Figures 9
2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 11
3 Disease Overview 13
3.1 Etiology and Pathophysiology 15
3.1.1 Diabetic Nephropathy 15
3.1.2 Diabetic Retinopathy 17
3.1.3 Diabetic Neuropathy 18
3.2 Prognosis 19
3.3 Quality of Life 20
3.4 Symptoms 21
4 Disease Management 22
4.1 Treatment Overview 22
4.1.1 Diagnosis and Referrals 22
4.1.2 Screening 24
4.1.3 Treatment Guidelines 25
5 Competitive Assessment 33
5.1 Overview 33
5.2 Strategic Competitor Assessment 34
6 Opportunity and Unmet Need 38
6.1 Overview 38
6.2 Unmet Needs 39
6.2.1 Unified Treatment for the Microvascular Complications of Diabetes 39
6.2.2 Optimization of Personalized Therapy in the Microvascular Complications of Diabetes 39
6.2.3 Treatment for Diabetic Nephropathy that Would Prevent ESRD 41
6.2.4 Cardio- and Renoprotective Therapy for Diabetic Nephropathy 42
6.2.5 Efficient Therapy for Retinopathy 43
6.2.6 Convenient Administration in Diabetic Retinopathy Treatment 43
6.2.7 Treatment for Diabetic Neuropathy 44
6.3 Unmet Needs Gap Analysis 45
6.4 Opportunity: Therapy for the Underlying Cause of the Microvascular Complications of Diabetes 47
6.5 Opportunity: Patient-Tailored Therapy for the Microvascular Complications of Diabetes 47
6.6 Opportunity: Efficacious Therapy for Diabetic Nephropathy 48
6.7 Opportunity: Topical Treatment for Diabetic Retinopathy 48
6.8 Opportunity: Treatment for Diabetic Neuropathy 49
7 Pipeline Assessment 50
7.1 Overview 50
7.2 Promising Drugs in Clinical Development 52
8 Atrasentan Hydrochloride 54
8.1 Overview 54
8.2 Efficacy 55
8.3 Safety 56
8.4 Dosing and Formulation 56
8.5 Potential Clinical Positioning 56
8.6 Potential Commercial Positioning 57
8.7 Pricing and Reimbursement 57
8.8 SWOT Analysis 58
8.9 Forecast 58
9 Appendix 60
9.1 Bibliography 60
9.2 Abbreviations 64
9.3 Methodology 66
9.4 Forecasting Methodology 66
9.4.1 Diagnosed Patients 66
9.4.2 Percent Drug-Treated Patients 67
9.4.3 General Pricing Assumptions 67
9.4.4 Generic Erosion 68
9.4.5 Pricing of Pipeline Agents 68
9.5 Physicians and Specialists Included in this Study 69
9.6 About the Authors 71
9.6.1 Analyst II – CVMD 71
9.6.2 Therapy Director – CVMD and Infectious Disease 71
9.6.3 Global Head of Healthcare 72
9.7 About GlobalData 73
9.8 Disclaimer 73